Human Reproduction, Vol. 15, No. 6, 1266-1274,
June 2000
© 2000 European Society of Human Reproduction and Embryology
Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome
1 Department of Obstetrics and Gynecology and 2 Department of Clinical Chemistry, University Hospital of Oulu and 3 Department of Internal Medicine, University Hospital of Kuopio, Finland
To study the contributions of body mass, body fat distribution and family history of type 2 diabetes mellitus to hyperinsulinaemia, insulin secretion and resistance in polycystic ovarian syndrome (PCOS), 17 lean (LC) and 17 obese (OC) healthy control subjects, and 15 lean (LPCOS) and 28 obese (OPCOS) women with PCOS were investigated. Waist:hip ratio (WHR), serum concentrations of sex steroids, glucose and insulin during a 75 g oral glucose tolerance test (OGTT), and insulin and C-peptide early phase secretion, and insulin sensitivity index using a euglycaemic hyperinsulinaemic clamp were assessed. The PCOS subjects had a higher mean WHR than the controls. A trend towards hyperinsulinaemia and impairment of insulin sensitivity (including the rates of both glucose oxidation and non-oxidation) was observed in LPCOS subjects, but only in OPCOS subjects were these changes significant. Early phase insulin secretion but not the early phase C-peptide secretion was increased in PCOS subjects compared to controls, suggesting that peripheral hyperinsulinaemia in PCOS women was mainly due to the observed lowered hepatic insulin extraction and insulin resistance in skeletal muscle. Moreover, the presence of a family history of type 2 diabetes did not affect early phase insulin or C-peptide secretion in the PCOS group. These results confirm and strengthen earlier contentions, that insulin resistance is a characteristic defect in PCOS and is worsened particularly by abdominal obesity.
Key words: early phase secretion of insulin/insulin sensitivity/polycystic ovarian syndrome
4 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, University Hospital of Oulu, Kajaanintie 52, 90220, Finland. E-mail: juha.tapanainen{at}oulu.fi
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. M. Barber, M. Hazell, C. Christodoulides, S. J. Golding, C. Alvey, K. Burling, A. Vidal-Puig, N. P. Groome, J. A. H. Wass, S. Franks, et al. Serum Levels of Retinol-Binding Protein 4 and Adiponectin in Women with Polycystic Ovary Syndrome: Associations with Visceral Fat But No Evidence for Fat Mass-Independent Effects on Pathogenesis in This Condition J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2859 - 2865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Svendsen, L. Nilas, K. Norgaard, J.-E. B. Jensen, and S. Madsbad Obesity, body composition and metabolic disturbances in polycystic ovary syndrome Hum. Reprod., June 12, 2008; (2008) den211v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Barber, S. J. Golding, C. Alvey, J. A. H. Wass, F. Karpe, S. Franks, and M. I. McCarthy Global Adiposity Rather Than Abnormal Regional Fat Distribution Characterizes Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Manneras, S. Cajander, A. Holmang, Z. Seleskovic, T. Lystig, M. Lonn, and E. Stener-Victorin A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome Endocrinology, August 1, 2007; 148(8): 3781 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hahn, U. H Frey, W. Siffert, S. Tan, K. Mann, and O. E Janssen The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. Eur. J. Endocrinol., November 1, 2006; 155(5): 763 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions. Diabetes Care, September 1, 2006; 29(9): 2165 - 2174. [Full Text] [PDF]
|
|
|
|
|
|
G. Gennarelli, V. Rovei, R. F. Novi, J. Holte, F. Bongioanni, A. Revelli, G. Pacini, P. Cavallo-Perin, and M. Massobrio Preserved Insulin Sensitivity and {beta}-Cell Activity, but Decreased Glucose Effectiveness in Normal-Weight Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3381 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Rautio, J S Tapanainen, A Ruokonen, and L C Morin-Papunen Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome Eur. J. Endocrinol., February 1, 2005; 152(2): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schuster, T. Gaillard, S. Rhinesmith, D. Habash, and K. Osei Impact of Metformin on Glucose Metabolism in Nondiabetic, Obese African Americans: A placebo-controlled, 24-month randomized study Diabetes Care, November 1, 2004; 27(11): 2768 - 2769. [Full Text] [PDF]
|
|
|
|
|
|
T. Piltonen, R. Koivunen, A. Perheentupa, L. Morin-Papunen, A. Ruokonen, and J. S. Tapanainen Ovarian Age-Related Responsiveness to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3769 - 3775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cibula Is insulin resistance an essential component of PCOS?: The influence of confounding factors Hum. Reprod., April 1, 2004; 19(4): 757 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A.M. de Boer, C. B. Lambalk, H. H. Hendriks, C. van Aken, E. A. van der Veen, and J. Schoemaker Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome Hum. Reprod., March 1, 2004; 19(3): 504 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Morin-Papunen, K. Rautio, A. Ruokonen, P. Hedberg, M. Puukka, and J. S. Tapanainen Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4649 - 4654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Silfen, M. R. Denburg, A. M. Manibo, R. A. Lobo, R. Jaffe, M. Ferin, L. S. Levine, and S. E. Oberfield Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4682 - 4688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Korhonen, S. Heinonen, M. Hiltunen, S. Helisalmi, M. Hippelainen, R. Koivunen, J.S. Tapanainen, and M. Laakso Polymorphism in the peroxisome proliferator-activated receptor-{gamma} gene in women with polycystic ovary syndrome Hum. Reprod., March 1, 2003; 18(3): 540 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J. S. Tapanainen Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 148 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cermik, B. Selam, and H. S. Taylor Regulation of HOXA-10 Expression by Testosterone in Vitro and in the Endometrium of Patients with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 238 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Elter, G. Imir, and F. Durmusoglu Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study Hum. Reprod., July 1, 2002; 17(7): 1729 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vrbikova, B. Bendlova, M. Hill, M. Vankova, K. Vondra, and L. Starka Insulin Sensitivity and {beta}-Cell Function in Women With Polycystic Ovary Syndrome Diabetes Care, July 1, 2002; 25(7): 1217 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Piltonen, R. Koivunen, L. Morin-Papunen, A. Ruokonen, I.T. Huhtaniemi, and J.S. Tapanainen Ovarian and adrenal steroid production: regulatory role of LH/HCG Hum. Reprod., March 1, 2002; 17(3): 620 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ciampelli, F. Leoni, F. Lattanzi, M. Guido, R. Apa, and A. Lanzone A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome Hum. Reprod., March 1, 2002; 17(3): 647 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ciampelli, G. Muzj, F. Leoni, D. Romualdi, C. Belosi, R. M. Cento, and A. Lanzone Metabolic and Endocrine Consequences of Acute Suppression of FFAs by Acipimox in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5324 - 5329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Koivunen, J. Juutinen, I. Vauhkonen, L. C. Morin-Papunen, A. Ruokonen, and J. S. Tapanainen Metabolic and Steroidogenic Alterations Related to Increased Frequency of Polycystic Ovaries in Women with a History of Gestational Diabetes J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2591 - 2599. [Abstract] [Full Text] [PDF]
|
|